Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-09-19
2006-09-19
Canella, Karen A. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C424S093210, C424S093700, C424S277100
Reexamination Certificate
active
07109026
ABSTRACT:
The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.
REFERENCES:
patent: 0 385 909 (1990-09-01), None
patent: 0 394 827 (1990-10-01), None
patent: 89 02922 (1989-04-01), None
patent: 90 01870 (1990-03-01), None
patent: 91 10682 (1991-07-01), None
patent: WO 94/16737 (1994-08-01), None
patent: 95 21528 (1995-08-01), None
patent: 95 30750 (1995-11-01), None
patent: 96 04386 (1996-02-01), None
patent: 96 17874 (1996-06-01), None
patent: 96 20215 (1996-07-01), None
patent: 97 24132 (1997-07-01), None
Abstract of Jacob et al, Indian J Cancer. Jun. 2002;39(2):61-5.
Abstract of Mauro et al, Curr Opin Oncol. Jan. 2001;13(1):3-7.
Abstract of Kollalexi et al, Anticancer Res. Jul.-Aug.;18(4A):2359-64.
Abstract of Dorak et al (Leuk Lymphoma. Jan. 1994;12(3-4):211-22).
Abstract of Bortin et al (Blood. Jul. 1987;70(1):227-32).
Abstract of Haas et al (Nature. Oct. 1, 1992;359(6394):414-6).
Abstract of Makni et al (J Immunol. Apr. 15, 1991;46(8):2522-9).
Abstract of Azuma et al (J Immunol. Aug. 15, 1992;149(4):1115-23).
Abstract of Baron et al (Eur J Immunol. Aug. 1994;24(8):1933-6).
Abstract of Altenschmidt et al (Clin Cancer Res. Jun. 1996;2(6):1001-8).
Huard et al (PNAS, May 1997, vol. 94, pp. 5744-5749).
Abstract of Baron et al (Eur J Immunol. Aug. 1994;24(8):1933-6).
Huard et al., CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins,Eur. J. Immunol., vol. 25, pp. 2718-2721, (1995).
McKinney et al., “A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid”,Journal of Immunological Methods, vol. 96 pp. 271-278, (1987).
Tighe et al., “Gene vaccination: plasmid DNA is more than just a blueprint”,Immunology Today, vol. 19, No. 2, pp. 89-97, (1998).
Brunoquel et al., “Genomic Organization of the Human LAG-3/CD4 locus”,Immunogenetics, vol. 47, pp. 96-98, (1997).
Koch et al., “High Level IL-12 Production by Murine Dendritic Cells: Upregulation via MHC Class II and CD40 Molecules and Downregulation by IL-4 and IL-10”,J.Exp. Med., vol. 184, pp. 741-746, (1996).
Wade et al. “Structural compartmentalization of MHC class II signaling function”,Immunology Today, vol. 14, No. 11, pp. 539-546, (1993).
Pardoll et al., “Paracrine Cytokine Adjuvants in Cancer Immunotherapy”,Annu. Rev. Immunol., vol. 13, pp. 399-415, (1995).
Restifo et al., “Biology of Cellular Immune Response”,Biological Therapy of Cancer, pp. 3-37 (1995).
Cosgrove et al., “Mice Lacking MHC Class II Molecules”,Cell, vol. 66, pp. 1051-1066, (1991).
Takebe et al., “SRα Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-cell Leukemia Virus Type 1 Long Terminal Repeat”,Molecular and Cellular Biology, vol. 8, No. 1, pp. 466-472, (1988).
Chen et al., “Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4”,Cell, vol. 71, pp. 1093-1102, (1992).
Angevin et al., “Analysis of T-cell Immune Response in Renal Cell Carcinoma: Polarization to Type 1-Like Differentiation Pattern, Clonal T-cell Expansion and Tumor-Specific Cytotoxicuty”,Int. J. Cancer, vol. 72, pp. 431-440, (1997).
Miyazaki et al., “Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3”,Science, vol. 272, pp. 405-408, (1996).
Huard et al., “T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding”,Eur. J. Immunol., vol. 26, pp. 1180-1186, (1996).
Huard et al., “Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes”,Eur. J. Immunol., vol. 24, pp. 3216-3221, (1994).
Huard et al., “Characterization of the major histocompatibility complex class II binding site on LAG-3 protein”,Proc. Natl. Acad. Sci, vol. 94 pp. 5744-5749, (1997).
Huard et al., “Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand”,Immunogentics, vol. 39, pp. 213-217, (1994).
Triebel et al., “LAG-3 a Novel Lymphocyte Activation Gene Closely Related to CD4”,J. Exp. Med., vol. 171, pp. 1393-1405, (1990).
Huard et al., “T cell MHC Class II Molecules Downregulated T Cell Proliferation following LAG-3 Binding”,Eur. J. Immunol., vol. 25, pp. 2718-2721, (1995).
Baixeras et al., “Characterization of the Lymphocyte Activation Gene 3-Encoded Protein. A New Ligand for Human Leukocyte Antigen Class II Antigens”,J. Exp. Med, vol. 176, pp. 327-337, (1992).
Wahren, “Gene Vaccines”,Immunotechnology, vol. 2, pp. 77-83, (1996).
Dranoff et al., “Prospects for the Immunotherapy of Cancer Using Genetically Modified Tumors Cells”,Klinische Pharmakologie, vol. 9, pp. 22-29, (1992).
Williams et al., “Genetic Infection Induces Protective In Vivo Immune Responses”,DNA and Cell Biology, vol. 12, No. 8, pp. 675-683, (1993).
Huard et al., “Cellular expression and tissue distribution of the Human LAG-3-encoded protein, an MHC Class II ligand”,Immunogenetics, vol. 39, pp. 213-217, (1994).
Faure et al., “Soluble polypeptide fractions of the LAG-3 protein”, NCBI, PubMed Database, Accession No. AAE27624 (2000).
Lazar et al., “Transforming growth factor alpha: Mutation of Aspartic Acid 47 and Leuine 48 results in different biological activities”,Molecular and Cellular Biology, 8:1247-1252 (1988).
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue”,Journal of Cellular Biology, 111 (1990).
Kang et al., “Immunization with soluble CD4-gp 120 complex preferentially induces neutralizing anti-human immunodeficiency virus type I antibodies”,Journal of Virology, 68(9)5854-5862 (1994).
Pelikan et al., Autoimmune mechanisms in the pathogenesis of neurologic paraneoplastic diseases (Abstract only), Bratislavske Lekarske Listy, 98(6)335-338 (1997).
Abbas et al., Cellular and Molecular Immunology, 153-155 (1991).
Applied Research Systems ARS Holding N.V.
Browdy and Neimark PLLC
Canella Karen A.
Institut Gustave Roussy
LandOfFree
Use of MHC class II ligands as adjuvant for vaccination and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of MHC class II ligands as adjuvant for vaccination and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of MHC class II ligands as adjuvant for vaccination and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567874